Highlights Alzinova AB

Equities

ALZ

SE0007413455

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
1.75 ^SEK	+8.02%		+28.68%	-42.34%

Jul. 09	Alzinova AB Announces All Patients in the High-Dose Cohort of the Phase 1B Study	CI
Jun. 18	Alzinova AB Announces All Patients Have Been Recruited in the High-Dose Part of Alzinova's Phase 1B Study	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alzinova AB Announces All Patients in the High-Dose Cohort of the Phase 1B Study	Jul. 09	CI
Alzinova AB Announces All Patients Have Been Recruited in the High-Dose Part of Alzinova's Phase 1B Study	Jun. 18	CI
Alzinova AB Announces New External Safety Review for Phase 1b Study	Jun. 10	CI
Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 28	CI
Alzinova AB Announces the First Patient Dosed with A Higher Dose in the Company's Phase 1B Study (Part A2) with the Vaccine Candidate ALZ-101	May. 21	CI
Alzinova AB Completes In-Depth Analysis of Data from Part A of Alzinova's Phase 1B Study with the Vaccine Candidate ALZ-101	Apr. 11	CI
Alzinova AB Announces All Patients in the Extension Part of the Phase 1B Study Have Received Their Last Dose of ALZ-101	Apr. 04	CI
Alzinova AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Alzinova Secures Regulatory Approval to Test Higher Dose of Vaccine Candidate in Ongoing Trial	Feb. 13	MT
Alzinova AB Receives Regulatory Approval to Evaluate A Higher Dose of the Vaccine Candidate Alz-101 in the Ongoing Phase 1B Study	Feb. 13	CI
Alzinova AB Announces Primary Analysis Confirms Positive Phase 1B Results with ALZ-101 against Alzheimer's	Jan. 30	CI
Alzinova AB Announces Positive Phase 1b Results with the Vaccine Candidate ALZ-101 Against Alzheimer's Disease	Nov. 29	CI
Alzinova AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
EU Medicines Regulator OKs Alzinova's Clinical Development Program for Alzheimer's Drug Candidate	23-09-26	MT
Alzinova AB Receives Positive Response from the European Medicines Agency EMA	23-09-26	CI
Alzinova Enters Peptide Production Agreement with Manufacturer	23-08-25	MT
Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Alzinova AB Successfully Concludes A Pre-IND Meeting with the US Food and Drug Administration Receiving Positive Feedback on the Planned Clinical Development Program for the Vaccine Candidate ALZ-101	23-08-09	CI
Alzinova AB Submits Request for Pre-IND Meeting with FDA and Applies for EMA Scientific Advice	23-06-13	CI
Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alzinova AB

Equities

ALZ

SE0007413455

Highlights

Filters